DW-0929

DW-0929 is a **small molecule drug** developed for the treatment of **primary hypercholesterolemia**, a condition characterized by elevated cholesterol levels in the blood[1][5][7][9]. It is being investigated in late-stage clinical trials, notably a completed Phase 3 study aimed at evaluating its efficacy and safety specifically for patients with primary hypercholesterolemia[1][5][7][9]. The mechanism of action and molecular target(s) for DW-0929 are not publicly described in available sources, and there is no publicly available evidence that DW-0929 corresponds to a previously approved active pharmaceutical ingredient. The **developer and sponsor** for DW-0929 is Daewon Pharmaceutical[1][5][7]. Currently, DW-0929 has not received regulatory approval in the United States (FDA), Europe (EMA), Singapore (HSA), China (NMPA), Kenya (PPB), or Australia (TGA)[5]. No additional clinical indications are listed outside of primary hypercholesterolemia. No details on combination status, biosimilar, generic, or formulation relationships are available. No information is available regarding manufacturing entities beyond the developer. No information is available regarding the molecular targets, mechanism of action, or route of administration.

Brand names

DW-0929DW0929DW 0929

Other names

DW-0929DW0929DW 0929